

12 September 2018

Omni Innovation: Update by Eagle Health

EVE Investments provides for your information a copy of a release made by Eagle Health Holdings (ASX:EHH) today which included an update on the CFDA registration process for the Chinese market.

Omni Innovation, a medical technology company focused on medical nutrition and in which EVE has a ~38% interest, has a licence agreement in place with Eagle Health for the manufacture and distribution of its pre-meal drink for people with Type 2 diabetes and pre-diabetes.

About Omni Innovation

Omni Innovation creates unique and specialised medical food products that can be used by people with chronic and lifestyle diseases. Omni's products are independently validated and supervised by Omni's expert collaborator network to ensure that customers have safe, effective and clinically tested products that provide benefit with scientific backing.

About Eagle Health Holdings Limited

Eagle Health Holdings Limited is a vertically integrated consumer health and nutritional products business which develops, manufactures and distributes its product range across 26 provinces in China. Eagle Health produces a range of traditional Chinese and Western nutritional and dietary supplements including amino acids, protein supplements, lozenges and dendrobium. The Company distributes its products through a broad range of channels, including pharmacies, health food stores, trading companies, supermarkets and online stores.

About EVE Investments

EVE Investments invests in technology companies with a focus on the medical nutrition sector. The Company's investment strategy has a three-pronged approach.

1. To invest in businesses that are in the early growth phase with the aim to support their expansion programs.
2. To identify products that have unique medicinal properties and a global reach application.
3. Preference for natural organic products that have demonstrated medicinal benefits.

For further information, please visit www.eveinvestments.com.au and follow us on Twitter [@EVEInvestments](https://twitter.com/EVEInvestments)

For further information:

Ben Rohr

Investment Director

+ 61 8 6465 5500

benr@eveinvestments.com.au



Eagle Health Holdings Limited

ASX Announcement
12 September 2018

Eagle Health Product Registration Update

Eagle Health Holdings Limited (ASX: EHH) (“Eagle Health” or “Company”) wishes to update shareholders on the registration progress for the Company’s pre-meal shake product for Type 2 diabetes and Pre-Type 2 diabetes, Hutang 1, to be registered as a Food for Special Medical Purpose (FSMP).

Eagle Health exclusively manufactures, markets and distributes the Australian clinically proven Hutang 1. The product is currently sold as a Functional Food Product via the Company’s Education and Experience stores.

As Hutang 1 is a product designed to aide in the assistance of Type 2 diabetes and Pre-Type 2 diabetes, Eagle Health has applied for registration of the product formula including the Company’s high-speed line, with the CFDA¹ as a FSMP.

During the FSMP registration process, which includes the product formula as well as the Company high speed line, the CFDA have restricted Hutang 1 promotional activity, impacting on the company’s ability to drives sales. The Company expects the FSMP regsitration process to be completed by Q4 2019.

Mr Zhang Ming Wang, Managing Director of Eagle Health, said:

“According to the International Diabetes Federation (IDF) 2017 Diabetes Atlas China has over 114 million people with diabetes with this number forcast to increase. We look forward to receiving registration from the authorities to sell the product as a Food for Special Medical Purpose and provide these patients with the support they need to manage their condition.”

The Company will continue to update the market on registration progress accordingly.

About Eagle Health Holdings Limited

Eagle Health Holdings Limited is a vertically integrated consumer health and nutritional products business which develops, manufactures and distributes its product range across 26 provinces in China. Eagle Health produces a range of traditional Chinese and Western nutritional and dietary supplements including amino acids, protein supplements, lozenges and dendrobium. The Company distributes its products through a broad range of channels, including pharmacies, health food stores, trading companies, supermarkets and online stores.

¹ (CFDA) - China Food & Drug Administration

For more information visit: www.auehh.com.au or www.eaglehealthltd.com/EN/index.aspx

CONTACT:

Eagle Health

Steven Shao

Investor Relations

T: +61 3 8593 7378

steven@aeuhh.com.au

Investor Enquiries

David Allen / John Granger

Hawkesbury Partners

T: +61 2 9103 9494

dallen@hawkesburypartners.com

Media Relations

Rod North Managing Director

Bourse Communications Pty Ltd

T: +61 3 9510 8309

rod@boursecommunications.com.au

For personal use only